The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Antidiabetic Thiazolidinediones Market Research Report 2025

Global Antidiabetic Thiazolidinediones Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1901857

No of Pages : 93

Ask Your Query

Synopsis

The global Antidiabetic Thiazolidinediones market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Antidiabetic Thiazolidinediones, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antidiabetic Thiazolidinediones.

Report Scope

The Antidiabetic Thiazolidinediones market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antidiabetic Thiazolidinediones market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Antidiabetic Thiazolidinediones manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • Sanofi
  • Takeda Pharmaceuticals
  • Eli Lilly
  • Merck & Co.
  • Novo Nordisk
  • Bristol-Myers Squibb
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Boehringer Ingelheim

Segment by Type

  • Rosiglitazone
  • Pioglitazone

Segment by Application

  • Hospitals
  • Clinics
  • Other

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antidiabetic Thiazolidinediones manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antidiabetic Thiazolidinediones in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Index

1 Antidiabetic Thiazolidinediones Market Overview
1.1 Product Overview and Scope of Antidiabetic Thiazolidinediones
1.2 Antidiabetic Thiazolidinediones Segment by Type
1.2.1 Global Antidiabetic Thiazolidinediones Market Value Comparison by Type (2024-2030)
1.2.2 Rosiglitazone
1.2.3 Pioglitazone
1.3 Antidiabetic Thiazolidinediones Segment by Application
1.3.1 Global Antidiabetic Thiazolidinediones Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Antidiabetic Thiazolidinediones Market Size Estimates and Forecasts
1.4.1 Global Antidiabetic Thiazolidinediones Revenue 2019-2030
1.4.2 Global Antidiabetic Thiazolidinediones Sales 2019-2030
1.4.3 Global Antidiabetic Thiazolidinediones Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Antidiabetic Thiazolidinediones Market Competition by Manufacturers
2.1 Global Antidiabetic Thiazolidinediones Sales Market Share by Manufacturers (2019-2024)
2.2 Global Antidiabetic Thiazolidinediones Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Antidiabetic Thiazolidinediones Average Price by Manufacturers (2019-2024)
2.4 Global Antidiabetic Thiazolidinediones Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antidiabetic Thiazolidinediones, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antidiabetic Thiazolidinediones, Product Type & Application
2.7 Antidiabetic Thiazolidinediones Market Competitive Situation and Trends
2.7.1 Antidiabetic Thiazolidinediones Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antidiabetic Thiazolidinediones Players Market Share by Revenue
2.7.3 Global Antidiabetic Thiazolidinediones Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antidiabetic Thiazolidinediones Retrospective Market Scenario by Region
3.1 Global Antidiabetic Thiazolidinediones Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Antidiabetic Thiazolidinediones Global Antidiabetic Thiazolidinediones Sales by Region: 2019-2030
3.2.1 Global Antidiabetic Thiazolidinediones Sales by Region: 2019-2024
3.2.2 Global Antidiabetic Thiazolidinediones Sales by Region: 2025-2030
3.3 Global Antidiabetic Thiazolidinediones Global Antidiabetic Thiazolidinediones Revenue by Region: 2019-2030
3.3.1 Global Antidiabetic Thiazolidinediones Revenue by Region: 2019-2024
3.3.2 Global Antidiabetic Thiazolidinediones Revenue by Region: 2025-2030
3.4 North America Antidiabetic Thiazolidinediones Market Facts & Figures by Country
3.4.1 North America Antidiabetic Thiazolidinediones Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Antidiabetic Thiazolidinediones Sales by Country (2019-2030)
3.4.3 North America Antidiabetic Thiazolidinediones Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Antidiabetic Thiazolidinediones Market Facts & Figures by Country
3.5.1 Europe Antidiabetic Thiazolidinediones Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Antidiabetic Thiazolidinediones Sales by Country (2019-2030)
3.5.3 Europe Antidiabetic Thiazolidinediones Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antidiabetic Thiazolidinediones Market Facts & Figures by Country
3.6.1 Asia Pacific Antidiabetic Thiazolidinediones Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Antidiabetic Thiazolidinediones Sales by Country (2019-2030)
3.6.3 Asia Pacific Antidiabetic Thiazolidinediones Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Antidiabetic Thiazolidinediones Market Facts & Figures by Country
3.7.1 Latin America Antidiabetic Thiazolidinediones Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Antidiabetic Thiazolidinediones Sales by Country (2019-2030)
3.7.3 Latin America Antidiabetic Thiazolidinediones Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antidiabetic Thiazolidinediones Market Facts & Figures by Country
3.8.1 Middle East and Africa Antidiabetic Thiazolidinediones Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Antidiabetic Thiazolidinediones Sales by Country (2019-2030)
3.8.3 Middle East and Africa Antidiabetic Thiazolidinediones Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antidiabetic Thiazolidinediones Sales by Type (2019-2030)
4.1.1 Global Antidiabetic Thiazolidinediones Sales by Type (2019-2024)
4.1.2 Global Antidiabetic Thiazolidinediones Sales by Type (2025-2030)
4.1.3 Global Antidiabetic Thiazolidinediones Sales Market Share by Type (2019-2030)
4.2 Global Antidiabetic Thiazolidinediones Revenue by Type (2019-2030)
4.2.1 Global Antidiabetic Thiazolidinediones Revenue by Type (2019-2024)
4.2.2 Global Antidiabetic Thiazolidinediones Revenue by Type (2025-2030)
4.2.3 Global Antidiabetic Thiazolidinediones Revenue Market Share by Type (2019-2030)
4.3 Global Antidiabetic Thiazolidinediones Price by Type (2019-2030)
5 Segment by Application
5.1 Global Antidiabetic Thiazolidinediones Sales by Application (2019-2030)
5.1.1 Global Antidiabetic Thiazolidinediones Sales by Application (2019-2024)
5.1.2 Global Antidiabetic Thiazolidinediones Sales by Application (2025-2030)
5.1.3 Global Antidiabetic Thiazolidinediones Sales Market Share by Application (2019-2030)
5.2 Global Antidiabetic Thiazolidinediones Revenue by Application (2019-2030)
5.2.1 Global Antidiabetic Thiazolidinediones Revenue by Application (2019-2024)
5.2.2 Global Antidiabetic Thiazolidinediones Revenue by Application (2025-2030)
5.2.3 Global Antidiabetic Thiazolidinediones Revenue Market Share by Application (2019-2030)
5.3 Global Antidiabetic Thiazolidinediones Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Corporation Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Sanofi Antidiabetic Thiazolidinediones Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 Takeda Pharmaceuticals
6.2.1 Takeda Pharmaceuticals Corporation Information
6.2.2 Takeda Pharmaceuticals Description and Business Overview
6.2.3 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Product Portfolio
6.2.5 Takeda Pharmaceuticals Recent Developments/Updates
6.3 Eli Lilly
6.3.1 Eli Lilly Corporation Information
6.3.2 Eli Lilly Description and Business Overview
6.3.3 Eli Lilly Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Eli Lilly Antidiabetic Thiazolidinediones Product Portfolio
6.3.5 Eli Lilly Recent Developments/Updates
6.4 Merck & Co.
6.4.1 Merck & Co. Corporation Information
6.4.2 Merck & Co. Description and Business Overview
6.4.3 Merck & Co. Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck & Co. Antidiabetic Thiazolidinediones Product Portfolio
6.4.5 Merck & Co. Recent Developments/Updates
6.5 Novo Nordisk
6.5.1 Novo Nordisk Corporation Information
6.5.2 Novo Nordisk Description and Business Overview
6.5.3 Novo Nordisk Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novo Nordisk Antidiabetic Thiazolidinediones Product Portfolio
6.5.5 Novo Nordisk Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Antidiabetic Thiazolidinediones Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 AstraZeneca
6.8.1 AstraZeneca Corporation Information
6.8.2 AstraZeneca Description and Business Overview
6.8.3 AstraZeneca Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2019-2024)
6.8.4 AstraZeneca Antidiabetic Thiazolidinediones Product Portfolio
6.8.5 AstraZeneca Recent Developments/Updates
6.9 GlaxoSmithKline
6.9.1 GlaxoSmithKline Corporation Information
6.9.2 GlaxoSmithKline Description and Business Overview
6.9.3 GlaxoSmithKline Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2019-2024)
6.9.4 GlaxoSmithKline Antidiabetic Thiazolidinediones Product Portfolio
6.9.5 GlaxoSmithKline Recent Developments/Updates
6.10 Boehringer Ingelheim
6.10.1 Boehringer Ingelheim Corporation Information
6.10.2 Boehringer Ingelheim Description and Business Overview
6.10.3 Boehringer Ingelheim Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Boehringer Ingelheim Antidiabetic Thiazolidinediones Product Portfolio
6.10.5 Boehringer Ingelheim Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antidiabetic Thiazolidinediones Industry Chain Analysis
7.2 Antidiabetic Thiazolidinediones Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antidiabetic Thiazolidinediones Production Mode & Process
7.4 Antidiabetic Thiazolidinediones Sales and Marketing
7.4.1 Antidiabetic Thiazolidinediones Sales Channels
7.4.2 Antidiabetic Thiazolidinediones Distributors
7.5 Antidiabetic Thiazolidinediones Customers
8 Antidiabetic Thiazolidinediones Market Dynamics
8.1 Antidiabetic Thiazolidinediones Industry Trends
8.2 Antidiabetic Thiazolidinediones Market Drivers
8.3 Antidiabetic Thiazolidinediones Market Challenges
8.4 Antidiabetic Thiazolidinediones Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock